Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Puma Biotechnology | Evaluate
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology
Puma Biotechnology Surging
Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Annual Report 2021
Puma Biotechnology
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology (PBYI) Stock Price, News & Info | The Motley Fool
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer | Business Wire
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
PumaBiotech on Twitter: "At Puma Biotechnology, our focus is on helping #cancer patients. We understand the #HER2 #breastcancer population faces challenges well beyond the point of care. We strive to empower patients
Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review
Puma Biotechnology Announces New Updates And Changes In Breast Cancer Treatment
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
